Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis
Information source: Loyola University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteomyelitis
Intervention: piperacillin/tazobactam, cefepime, metronidazole, aztreonam,vancomycin, daptomycin, linezolid ,meropenem (Drug); sulfamethoxazole/trimethoprim , clindamycin ,linezolid, moxifloxacin ,ciprofloxacin ,metronidazole (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Loyola University Official(s) and/or principal investigator(s): Michael Pinzur, M.D., Principal Investigator, Affiliation: Loyola University
Overall contact: Laurie Labuszewski, Pharm.D., Phone: 708-216-2307, Email: llabuszewski@lumc.edu
Summary
The Infectious Diseases Society of America (IDSA) 2012 guidelines for the diagnosis and
treatment of diabetic foot infections state that for the treatment of diabetic foot
osteomyelitis "No data support the superiority of any specific antibiotic agent or treatment
strategy, route, or duration of therapy." Traditionally, osteomyelitis has been treated with
a long course of intravenous antibiotics, generally six weeks. Oral antibiotics with high
bioavailability and adequate bone penetration have been shown in published studies to be
effective for the treatment of osteomyelitis.
The investigators propose to conduct a prospective, single-center, randomized, open trial at
Loyola University Medical Center (LUMC) comparing the efficacy of oral antibiotic therapy to
intravenous (IV) antibiotic therapy for the treatment of diabetic foot osteomyelitis. The
investigators hypothesize that oral antibiotic therapy is equivalent to IV antibiotic
therapy.
Bone/tissue cultures are obtained for all patients for clinical purposes and are sent to
pathology for histologic examination and to the clinical microbiology laboratory for culture
and susceptibility.
Patients will receive six weeks of IV or oral antibiotic therapy depending upon their
randomization group. Primary outcomes at six months clinical follow-up will include: (i) no
evidence of bone infection and (ii) resolution of ulcer.
Clinical Details
Official title: Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS)
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Bone Infection
Secondary outcome: Resolution of Ulcer
Detailed description:
Currently available literature is not adequate to determine the best agent, route, or
duration of antibiotic therapy for the treatment of chronic osteomyelitis. The standard of
therapy has been to treat patients with a parenteral antibiotic for four to six weeks. In a
recent literature review by Spellberg et al. it was concluded that oral and parenteral
antibiotic therapy have similar cure rates for the treatment of chronic osteomyelitis. Oral
antibiotic therapy is associated with a lower risk to the patient due to avoiding the need
of a central IV line. Additionally, oral therapy costs less than a course of IV
antibiotics. Oral antibiotics with high bioavailability and good bone penetration include,
fluoroquinoles, linezolid, trimethoprim/sulfamethoxazole (2 tabs bid), clindamycin and
metronidazole. These antibiotics have been shown in recent studies to obtain levels in the
bone that exceed MIC's of the targeted organisms.
According to the IDSA 2012 guidelines for the treatment of diabetic foot infections, the
diagnosis of osteomyelitis can be made via plain radiographs or MRI imaging (more
sensitive). A bone scan can be considered if an MRI cannot be done. The preferred method
of diagnosis is by bone culture and histology. The guidelines also recommend surgical
debridement to healthy tissue for diabetic foot infections followed by antibiotic therapy.
Study Aims
The Purpose of this study is to compare the efficacy of oral antibiotic therapy with IV
antibiotic therapy for the treatment of diabetic foot osteomyelitis following surgical
debridement.
Hypotheses: Oral Antibiotic Therapy is equivalent to IV Antibiotic Therapy for the Treatment
of Diabetic Foot Osteomyelitis.
Outcomes will be assessed at six months:
1. No evidence of bone infection. (absence of infection based on clinical examination and
down-trending of inflammatory markers)
2. Resolution of ulcer will be measured as yes or no (binary variable)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 18 years of age and older
- Diagnosis of Diabetes Mellitus (Per past medical history documented in the patient
medical record)
- Foot osteomyelitis (distal to ankle)
- Bone biopsy with histologic evidence of acute or chronic inflammation
- Surgical debridement (in operating room)
Exclusion Criteria:
- Absolute neutrophil count (ANC) < 500
- Pregnant or lactating patients
- Patients with organisms resistant to oral therapy
- Internal hardware
- Definitive amputations (BKA)
- Limb ischemia (absent pedal pulses or ABI < 0. 5)
- Bone biopsy histology negative for inflammation
- Negative bone/tissue cultures and no evidence of infection demonstrated on
microscopic examination
Locations and Contacts
Laurie Labuszewski, Pharm.D., Phone: 708-216-2307, Email: llabuszewski@lumc.edu
Loyola University Medical Center, Maywood, Illinois 60153, United States; Recruiting Laurie Labuszewski, Pharm.D., Phone: 708-216-2307, Email: llabuszewski@lumc.edu Tammy Rhoda, MPH, Phone: 708-216-5494, Email: trhoda@luc.edu Michael Pinzur, MD, Principal Investigator
Additional Information
Related publications: Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E, Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012 Jun;54(12):e132-73. doi: 10.1093/cid/cis346. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012 Feb 1;54(3):393-407. doi: 10.1093/cid/cir842. Epub 2011 Dec 12. Review. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis. 2005 May;9(3):127-38. Review. Bouazza N, Pestre V, Jullien V, Curis E, Urien S, Salmon D, Tréluyer JM. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Br J Clin Pharmacol. 2012 Dec;74(6):971-7. doi: 10.1111/j.1365-2125.2012.04292.x. Wukich DK, Armstrong DG, Attinger CE, Boulton AJ, Burns PR, Frykberg RG, Hellman R, Kim PJ, Lipsky BA, Pile JC, Pinzur MS, Siminerio L. Inpatient management of diabetic foot disorders: a clinical guide. Diabetes Care. 2013 Sep;36(9):2862-71. doi: 10.2337/dc12-2712. Review. Pinzur MS, Gil J, Belmares J. Treatment of osteomyelitis in charcot foot with single-stage resection of infection, correction of deformity, and maintenance with ring fixation. Foot Ankle Int. 2012 Dec;33(12):1069-74. doi: DOI: 10.3113/FAI.2012.1069.
Starting date: June 2014
Last updated: May 1, 2015
|